Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$0.40
EPS est.
$0.34
EPS surprise
+16.28%
1-day move
+13.88%
Elanco Animal Health reported better-than-expected earnings per share, which likely contributed to a strong stock reaction, with shares rising nearly 14%. However, there was no revenue figure provided, leaving some uncertainty about overall performance. Investors may view the EPS beat positively, but the lack of revenue details could lead to caution moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.40 | $0.34 | +16.28% |
| Revenue | — | $1.3B | — |
No transcript is on record, and the analysis is based on numerical results only.
Elanco Animal Health Incorporated focuses on providing products for animal health, including pharmaceuticals and vaccines for livestock and pets. As a key player in the health care sector, the company is significant for its role in ensuring animal well-being and food safety.
Last quarter
In the previous quarter, Elanco reported an EPS of $0.13, exceeding expectations by 16%. The stock reacted positively, gaining 6.59% the following day.
Management promises and guidance
EPS beat streak
6Q
EPS beat rate
88%
Avg EPS surprise
+20.20%
Avg 1-day reaction
+9.05%
Analysts expect Elanco to report solid earnings this quarter, with a consensus EPS of $0.34 and revenue of $1.3 billion. Investors will be closely watching for any signs of growth in key product areas.
Bull case
If Elanco beats EPS expectations and shows strong revenue growth, it could signal a recovery in demand and operational improvements, leading to a positive stock reaction.
Bear case
Conversely, if the company misses earnings expectations or provides weak guidance, it may raise concerns about its market position and growth prospects, resulting in a negative stock reaction.
Key metrics to watch
EPS
$0.34Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.
Revenue
$1.3BTotal revenue reflects the overall sales performance and market demand for Elanco's products, which is essential for assessing growth.
The print will turn on these.
Q1
Will Elanco's EPS exceed the consensus estimate of $0.34?
A beat on EPS could indicate stronger-than-expected profitability and operational efficiency, which would likely boost investor confidence.
Q2
What revenue growth can Elanco report compared to the expected $1.3 billion?
Revenue performance is crucial for assessing market demand and growth potential, and any significant deviation could impact stock sentiment.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate Elanco's ability to leverage its recent product innovations, which could drive stronger revenue growth than anticipated.
Supporting evidence
Elanco has a history of exceeding EPS expectations, with an 88% beat rate over the last eight quarters.
The options market indicates a significant expected move, suggesting traders anticipate volatility that could favor a positive outcome.
Key risk
If Elanco reports revenue growth significantly above $1.3 billion, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Elanco can maintain its growth trajectory amid competitive pressures and operational challenges.
Bull confirmed if
An EPS of $0.36 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $0.32 would confirm the bear case, suggesting ongoing challenges in profitability.
What the market is pricing for the move.
Implied Move
±10.6%
Historical Avg
±11.0%
The options market is pricing in a significant move of about 10.6%, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±11.4% while ELAN has averaged ±11.0% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.8%
30d HV
38.4%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options pricing cheap in Health Care
Fade rate: 3 of 30 (10%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
115.25%
of float
Insider
1.21%
of float
Holders
695
institutions
Top Holders· as of Jun 2026
Dodge & Cox Inc.
67,397,025 sh · $1.5B
13.49%
-2.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Elanco beats expectations, history suggests a potential stock increase of around 12.8%, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.
Miss
A miss on earnings could lead to a decline of approximately 3.7%, reflecting investor disappointment and concerns about future performance.
The lines on the call that would change the story.
FMR, LLC
56,948,819 sh · $1.3B
11.40%
11.8%
Blackrock Inc.
48,849,973 sh · $1.1B
9.78%
2.6%
Primecap Management Company
45,445,012 sh · $1.0B
9.10%
-0.9%
T. Rowe Price Investment Management, Inc.
28,750,719 sh · $642.9M
5.75%
-17.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.